SEL120-34A HCl is primarily investigated for its potential in cancer treatment, particularly in targeting specific pathways involved in cell cycle regulation. It has shown promise in preclinical studies for its ability to inhibit certain kinases that play a critical role in cancer cell proliferation. This makes it a candidate for developing therapies for hematologic malignancies and solid tumors. Researchers are exploring its use in combination with other anticancer agents to enhance efficacy and overcome drug resistance. Additionally, its mechanism of action is being studied to better understand its impact on epigenetic regulation, which could open new avenues for treating various cancers. Clinical trials are ongoing to evaluate its safety, tolerability, and therapeutic potential in humans.